BioCorRx Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending September 30, 2025. The company generated net revenues of $635,224 for the three months ended September 30, 2025, a notable increase from zero revenues in the same period last year. For the nine months ending September 30, 2025, total revenues reached $948,362, compared to $7,665 for the same period in 2024. This growth is attributed primarily to the distribution sales of Lucemyra, an FDA-approved medication for opioid withdrawal, following the company's acquisition of related assets in March 2025.
Operating expenses for the third quarter of 2025 totaled $2,580,811, up from $1,659,721 in the prior year, reflecting increased research and development costs, which rose to $1,004,660 from $460,138. The company reported a net loss of $808,502 for the quarter, a decrease from a loss of $1,513,010 in the same quarter of 2024. For the nine-month period, the net loss was $3,037,545, down from $3,984,469 in the previous year. The reduction in net loss is attributed to increased revenues and decreased interest expenses, despite rising operating costs.
In terms of strategic developments, BioCorRx completed an asset purchase agreement with USWM, LLC, acquiring assets related to Lucemyra. This acquisition is expected to enhance the company's product offerings and market presence. Additionally, the company has been awarded multiple grants from the National Institutes of Health, including a significant $11 million grant for ongoing research into BICX104, a sustained-release naltrexone implant aimed at treating methamphetamine use disorder.
Operationally, BioCorRx has seen an increase in customer engagement, with the number of patients treated at licensed clinics rising significantly. The company reported grant receivables of $761,515 as of September 30, 2025, and recognized grant income of $867,130 for the quarter, up from $572,777 in the previous year. However, the company continues to face challenges, including a working capital deficit of $13.6 million and an accumulated deficit of $87.2 million, raising concerns about its ability to continue as a going concern without additional capital.
Looking ahead, BioCorRx plans to pursue further financing options, including private placements of equity and convertible debt, to support its operations and development activities. The company remains focused on expanding its product offerings and enhancing its market position, while also managing its operational costs and seeking strategic partnerships to bolster its financial stability.
About BioCorRx Inc.
BioCorRx Inc. develops and provides addiction treatment solutions focused on substance use disorders, including alcoholism and opioid addiction. Its core offerings include the BioCorRx® Recovery Program, combining cognitive behavioral therapy and medication-assisted treatment, and the UnCraveRx® Weight Loss Program. Through its subsidiary BioCorRx Pharmaceuticals, the company develops implantable naltrexone pellets for long-acting treatment. It serves healthcare providers and patients, leveraging proprietary therapies and pharmaceutical innovations in addiction and weight management.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.